Lexicon Pharmaceuticals
LXRX
122 hedge funds and large institutions have $700M invested in Lexicon Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 44 reducing their positions, and 15 closing their positions.
20% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 15
3% more funds holding
Funds holding: 119 → 122 (+3)
2.05% less ownership
Funds ownership: 101.53% → 99.48% (-2.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
36% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 44
39% less capital invested
Capital invested by funds: $1.15B → $700M (-$447M)
74% less call options, than puts
Call options by funds: $640K | Put options by funds: $2.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.61M |
| 2 |
Renaissance Technologies
New York
|
+$2.05M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.86M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.4M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$6.98M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.88M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.19M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.54M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.76M |
LXRX Hedge Fund Activity: Q4 2018 in Review
122 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2018, worth a combined $700M — down 39% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new LXRX positions and 15 closed out — a net gain of 3 holders — while 28 added to existing stakes and 44 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $2.61M. The largest seller was UBS AM, cutting an estimated $6.98M.
- 122 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2018, up from 119 in Q3 2018.
- Funds reported $700M of Lexicon Pharmaceuticals stock for Q4 2018, down 39% quarter-over-quarter.
- 18 funds opened new Lexicon Pharmaceuticals positions in Q4 2018 and 15 closed out, a net change of +3 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2018 was Citadel Advisors, an estimated $2.61M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2018 was UBS AM, an estimated $6.98M sold.
Based on aggregated 13F filings for Q4 2018.